A Phase 2 interventional study of ENX-102 and Placebo in Social Anxiety Disorder (SAD), sponsored by Engrail Therapeutics INC. Completed at 20 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Engrail Therapeutics INC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Phobia, Social with a site in United States — 23 open to participants now, 29 under way, 1 of them phase 3. Phobia, Social · United States.
Among the 187 studies in Phobia, Social with a site in United States, this one is the 122nd largest by enrollment of the 178 interventional ones that give a count, is one of 12 that started in 2025, is one of 25 in phase 2, and was the 178th registered.
368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.
Browse Phobia, Social studies →23 of the 187 studies in Phobia, Social with a site in United States are open now. Recruiting first, the newest first:
Jason Careri · Sites in United States
Ages 18–65
Andrew Wiese · Sites in United States
Ages 7–17
Newleos Therapeutics, Inc. · Sites in United States
Ages 18–65
Bradley Hospital · Sites in United States
Ages 5–18
Ohio State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 34 · Phase 3 21 · Phase 4 18
First in 1998; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 76 across 339 interventional studies indexed under Phobia, Social.
Median enrollment 64 across the 178 interventional studies, 184 across the 8 observational. Of the 146 that completed or were terminated, 59 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 187 have an industry lead sponsor. The 10 most frequent:
Engrail Therapeutics INC is the lead sponsor of 8 studies on the registry; none are open to participants now.
Engrail Therapeutics INC has 1 study filed under Phobia, Social — fewer than ten, so there is no comparison to draw.
13 of the studies in Phobia, Social with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07221578Phase 3Vanda PharmaceuticalsStudy to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | 2026-12 |
| NCT04663724New York State Psychiatric InstituteComputer - Based Treatment for Social Anxiety Disorder | 2026-11-30 |
| NCT07589621Florida State UniversitySafety Behavior Fading Versus Progressive Muscle Relaxation for Appearance Concerns | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
| NCT07028216Georgetown UniversityMindful Self-compassion for Anxiety and Depression: Impact of Delivery Method | 2026-12-17 |
Add all 13 to your calendar (.ics) → With an account.
Among the 187 studies in Phobia, Social with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 2 mg of ENX-102 in capsule form orally once daily for 6 weeks, followed by 2 weeks of tapered dose and up to 2 weeks of placebo in capsule form before and/or after the 8-week ENX-102 treatment period.
Drug: ENX-102
Participants will receive ENX-102 matching placebo in capsule once daily for 10 weeks
Other: Placebo
oral capsule
oral capsule
Change From Baseline on the Clinician-administered Liebowitz Social Anxiety Scale (LSAS) - Total score
The LSAS is a 24-item semi-structured interview measure of fear and avoidance experienced in a range of social and performance situations. The 24 items are divided into 2 subscales, 13 concerning performance anxiety \& 11 pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations (0=none, 1=mild, 2=moderate, 3= severe), and then the same items are rated regarding avoidance of the situation (0=never, 1=occasionally, 2=often, 3=usually). An overall global score (0 to 144) is calculated by adding total fear/anxiety and total avoidance scores. Higher scores indicated higher probability of social anxiety disorder.
Time frame: Baseline (Day 1) and Week 6
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Mar 2026, 6 months.
Of 15 phase 2 interventional studies under Phobia, Social, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ENX-102
Engrail Therapeutics INC